STU
Aclaris Therapeutics Inc (8AT) is listed on STU. As of 2026-03-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
The price-to-earnings (P/E) ratio for Aclaris Therapeutics Inc (8AT) is 18.00 (data as of 2026-03-24).
Dividend yield is not available in the current snapshot for Aclaris Therapeutics Inc (8AT). Check the MyAverix Finance app for the latest dividend data.
8AT is listed on STU.
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.